Drugs / ALECSAT
ALECSAT
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01984658 | Oct 2013 → Jan 2015 | malignant pancreatic neoplasm | CytoVac A/S | Completed | No outcome recorded |
| Phase 1 | NCT01422850 | Aug 2011 → Sep 2012 | hormone-resistant prostate carcinoma | CytoVac A/S | Completed | No outcome recorded |
| Phase 1 | NCT01588769 | Aug 2011 → Nov 2012 | glioblastoma | CytoVac A/S | Completed | No outcome recorded |
| Phase 1 | NCT00891345 | Apr 2009 → Jul 2010 | hormone-resistant prostate carcinoma | CytoVac A/S | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02799238 | Mar 2016 → Nov 2019 | glioblastoma | CytoVac A/S | Completed | No outcome recorded |
| Phase 2 | NCT02060955 | Feb 2014 → Jun 2015 | glioblastoma | CytoVac A/S | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALECSAT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01588769 ↗ |
| Known as | Autologous Lymphoid Effector Cells Specific Against Tumor | “We recently developed Autologous Lymphoid Effector Cells Specific Against Tumor (ALECSAT), a novel procedure for selecting, expanding and maturing polyclonal lymphocytes from...” PMID 41344991 ↗ Dec 2025 |
| Known as | Autologous Lymphoid Effector Cells Specific Against Tumor-cells | “Autologous Lymphoid Effector Cells Specific Against Tumor-cells (ALECSAT).” NCT01422850 ↗ |
| Action | Deplete | “It is the hypothesis that the cells administered during the therapy will attack the tumor cells and in this way stop or slow down the progression of disease.” NCT01422850 ↗ |
| Modality | Cell therapy | “ALECSAT is an autologous CBMP that is made from the patient's own blood cells.” NCT00891345 ↗ |
| Route | Intravenous | “Autologous activated CTL and NK-cells injected as a single intravenous injection.” NCT00891345 ↗ |